Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Three Doses of Botulinum Toxin in the Treatment of Moderate to Very Severe Glabellar Frown Lines

NCT02236312 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT02236312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02236312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Three Doses of Botulinum Toxin in the Treatment of Moderate to Very Severe Glabellar Frown Lines
Lead sponsor
Galderma R&D
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
May 31, 2015
Enrollment
359 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines